NEWBURYPORT, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), an innovative designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported that adjusted net income increased 13.8% to $11.9 million in the third quarter of 2023 from $10.4 million in the third quarter of 2022. Sales for the third quarter were $100.8 million compared to 2022 third quarter sales of $97.0 million. Adjusted net income increased 44.4% to $35.8 million for the nine-month period ended September 30, 2023 from $24.8 million in the same period of 2022. Sales for the nine-month period ended September 30, 2023 were $298.6 million compared to sales of $262.6 million in the same period in 2022. Adjusted net income is a non-GAAP term. Please see “Non-GAAP Financial Information” at the end of this news release.
“I am pleased with our Q3 results and progress on our growth initiatives, particularly our expansion plans in our low-cost country facilities,” said R. Jeffrey Bailly, Chairman & CEO. “For example, in the Dominican Republic we are adding 40,000 square feet, including 10,000 square feet of new clean room manufacturing space. We are adding new equipment and hiring additional employees with the goal of increasing our capacity to make robotic drapes by 60% to support both new programs and strong anticipated growth of current programs. While the start-up costs and related inefficiencies have reduced gross margins, we expect improved operating efficiencies when new equipment comes online and new employees are fully trained. We are also adding 15,000 square feet in Costa Rica to meet increasing demand. In Mexico, we completed the qualification process to begin producing catheter and guidewire packaging that was previously manufactured in Ireland and Rhode Island and shipped to Mexico, another cost cutting initiative.”
“After adjusting for the sale of our Molded Fiber unit in Q3 of 2022, organic revenue growth in Q3 was 5.6%, with Medical sales up 6.8%,” Bailly added. “Our growth was impacted by multiple customers delaying releases due to excess inventory in their systems. Due to Covid-related caution, many customers ordered safety stock inventory, which is reaching levels they feel are excessive. We anticipate this softness will be short-term in nature as they work down their inventories, and our growth should accelerate as we enter next year.”
“We are excited about our growth potential in 2024, which should benefit from the significant investments mentioned above,” Bailly said. “We are also continuing our efforts to identify strategic acquisition candidates that will increase our value to customers. High interest rates have slowed deal flow, but have increased our competitiveness against private equity buyers who typically rely on higher leverage than UFP does.”
Financial Highlights for Q3 and YTD 2023
- Sales for the third quarter increased 3.9% to $100.8 million, from $97.0 million in the same period of 2022. Year-to-date sales through September increased 13.7% to $298.6 million, from $262.6 million in the same period of 2022. Organic sales growth for the three- and nine-month periods ended September 30 was 5.6% and 16.9%, respectively.
- Third quarter sales to the medical market increased 6.8% to $87.1 million. Sales to all other markets decreased 11.2% to $13.7 million, largely due to the sale of Molded Fiber in the third quarter of 2022. Year-to-date sales to the medical market increased 23.3% to $257.1 million. Sales to all other markets decreased 23.3% to $41.5 million, largely due to the sale of Molded Fiber in the third quarter of 2022.
- Gross profit as a percentage of sales (“gross margin”) increased to 27.5% for the third quarter, from 26.3% in the same quarter of 2022. Gross margin for the nine-month period ended September 30, 2023 increased to 28.8% from 25.5% in the same period of 2022.
- Selling, general and administrative expenses (“SG&A”) for the third quarter increased to $12.5 million in 2023 compared to $11.8 million in the same quarter of 2022. For the nine-month period ended September 30, 2023, SG&A increased to $37.8 million from $33.9 million in the same period of 2022.
- Adjusted operating income grew 11.5% and 46.1% for the three- and nine-month periods ended September 30, 2023 when compared to the respective periods of 2022. GAAP operating income for the third quarter decreased to $15.0 million, from $26.0 million in the same quarter of 2022. For the nine-month period ended September 30, 2023, operating income increased to $44.9 million, from $44.5 million in the same period of 2022. Adjusted operating income is a non-GAAP term. Please see “Non-GAAP Financial Information” at the end of this news release.
- Adjusted net income increased 13.8% to $11.9 million in the third quarter of 2023 from $10.4 million in the third quarter of 2022. Adjusted net income increased 44.4% to $35.8 million for the nine months ended September 30, 2023 from $24.8 million in the same period of 2022. GAAP net income decreased to $11.7 million in the third quarter of 2023, from $19.5 million in the same period of 2022. GAAP net income of $33.3 million was consistent for the nine-month periods ended September 30, 2023 and 2022. Adjusted net income is a non-GAAP term. Please see “Non-GAAP Financial Information” at the end of this news release.
- Adjusted EBITDA increased to $19.3 million in the third quarter of 2023 from $17.5 million in the same period of 2022. Adjusted EBITDA increased to $60.2 million for the nine-month period ended September 30, 2023 from $44.9 million in the same period of 2022. See the reconciliation provided in Table 3. EBITDA and Adjusted EBITDA are Non-GAAP Financial Measures. Please see "Non-GAAP Financial Information" at the end of this news release.
About UFP Technologies, Inc.
UFP Technologies is an innovative designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The Company’s single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants.
| Consolidated Condensed Statements of Income | ||||||||||||||
| (in thousands, except per share data) | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||
| September 30, | September 30, | |||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||
| Net sales | $ | 100,784 | $ | 96,970 | $ | 298,575 | $ | 262,555 | ||||||
| Cost of sales | 73,034 | 71,447 | 212,479 | 195,575 | ||||||||||
| Gross profit | 27,750 | 25,523 | 86,096 | 66,980 | ||||||||||
| SG&A | 12,467 | 11,822 | 37,771 | 33,909 | ||||||||||
| Change in fair value of contingent consideration | 238 | 3,346 | 3,289 | 9,348 | ||||||||||
| Gain on sale of Molded Fiber Technology | - | (15,623 | ) | - | (15,623 | ) | ||||||||
| Loss (Gain) on sale of fixed assets | - | 3 | 108 | (6,206 | ) | |||||||||
| Acquisition costs | - | 10 | - | 1,027 | ||||||||||
| Operating income | 15,045 | 25,965 | 44,928 | 44,525 | ||||||||||
| Interest expense, net | 933 | 830 | 2,890 | 1,891 | ||||||||||
| Other (income) expense | (29 | ) | (104 | ) | 28 | (313 | ) | |||||||
| Income before income taxes | 14,141 | 25,239 | 42,010 | 42,947 | ||||||||||
| Income taxes | 2,447 | 5,699 | 8,694 | 9,620 | ||||||||||
| Net income | $ | 11,694 | $ | 19,540 | $ | 33,316 | $ | 33,327 | ||||||
| Net Income per share | $ | 1.53 | $ | 2.58 | $ | 4.37 | $ | 4.41 | ||||||
| Net income per diluted share | $ | 1.52 | $ | 2.56 | $ | 4.33 | $ | 4.37 | ||||||
| Weighted average common shares outstanding | 7,639 | 7,570 | 7,619 | 7,559 | ||||||||||
| Weighted average diluted common shares outstanding | 7,709 | 7,638 | 7,697 | 7,629 | ||||||||||
| Consolidated Condensed Balance Sheets | ||||||
| (in thousands) | ||||||
| (Unaudited) | ||||||
| September 30, | December 31, | |||||
| 2023 | 2022 | |||||
| Assets: | ||||||
| Cash and cash equivalents | $ | 6,376 | $ | 4,451 | ||
| Receivables, net | 60,968 | 55,117 | ||||
| Inventories | 69,777 | 53,536 | ||||
| Other current assets | 3,346 | 3,242 | ||||
| Net property, plant, and equipment | 60,687 | 58,072 | ||||
| Goodwill | 112,968 | 113,028 | ||||
| Intangible assets, net | 65,020 | 68,361 | ||||
| Other assets | 20,668 | 22,385 | ||||
| Total assets | $ | 399,810 | $ | 378,192 | ||
| Liabilities and equity: | ||||||
| Accounts payable | $ | 26,948 | $ | 19,961 | ||
| Current installments, net of long-term debt | 4,000 | 4,000 | ||||
| Other current liabilities | 25,640 | 32,000 | ||||
| Long-term debt, excluding current installments | 39,000 | 51,000 | ||||
| Other liabilities | 31,839 | 33,686 | ||||
| Total liabilities | 127,427 | 140,647 | ||||
| Total stockholders' equity | 272,383 | 237,545 | ||||
| Total liabilities and stockholders' equity | $ | 399,810 | $ | 378,192 | ||
Forward Looking Statements
Certain statements in this press release may be considered "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. In some cases, the reader can identify forward-looking statements by words such as "may," "should," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," or similar words. Forward-looking statements relate to expected financial or operating performance and/or future business prospects, events, and plans. Such statements include, but are not limited to: statements regarding our capital expenditure plans and hiring plans and the anticipated benefits to be realized as a result thereof; statements regarding production expectations and improving our operating efficiencies, customer order activity and capacity; statements regarding human capital; expectations regarding our liquidity and business opportunities; statements about our growth potential and strategies for growth; and any statements implying that we may be able to sustain or increase sales, earnings and earnings per share or sales, earnings and earnings per share growth rates. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could adversely affect our business and prospects, and otherwise cause actual results to differ materially from those anticipated by such forward-looking statements, or otherwise. These risks include, without limitation: risks relating to our ability to realize expected advantages of capital expenditures; risks relating to our ability to maintain increased levels of production, or to continue to increase production rates; risks relating to disruptions and delays in our supply chain; risks relating to onboarding, training and retaining new talent; risks relating to maintaining demand for our products; risks relating to the identification of suitable acquisition candidates and the successful, efficient execution of acquisition transactions and integration of any acquisition candidates; risks and uncertainties associated with increasing sales, earnings and earnings per share, as well as other risks and uncertainties that are detailed in the documents we file with the Securities and Exchange Commission (“SEC”). Accordingly, actual results may differ materially. Readers are referred to the documents we file with the SEC, specifically the last report on Form 10-K. The forward-looking statements contained herein speak only of our expectations as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise required by law.
Non-GAAP Financial Information
This news release includes non-generally accepted accounting principles (“GAAP”) performance measures. Management considers Adjusted Operating Income, Adjusted Net Income, EBITDA and Adjusted EBITDA, non-GAAP measures. The Company uses these non-GAAP financial measures to facilitate management's financial and operational decision-making, including evaluation of the Company’s historical operating results. The Company’s management believes these non-GAAP measures are useful in evaluating the Company’s operating performance and are similar measures reported by publicly listed U.S. competitors, and regularly used by securities analysts, institutional investors, and other interested parties in analyzing operating performance and prospects. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. By providing these non-GAAP measures, the Company’s management intends to provide investors with a meaningful, consistent comparison of the Company’s performance for the periods presented. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. The Company's definition of these non-GAAP measures may differ from similarly titled measures of performance used by other companies in other industries or within the same industry.
Contact: Ron Lataille
978-234-0926
| Table 1: Adjusted Operating Income Reconciliation | |||||||||||||
| (in thousands) | |||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||
| September 30, | September 30, | ||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||
| Operating income (GAAP) | $ | 15,045 | $ | 25,965 | $ | 44,928 | $ | 44,525 | |||||
| Adjustments: | |||||||||||||
| Acquisition Costs | - | 10 | - | 1,027 | |||||||||
| Change in fair value of contingent consideration | 238 | 3,346 | 3,289 | 9,348 | |||||||||
| Gain on sale of Molded Fiber | - | (15,623 | ) | - | (15,623 | ) | |||||||
| Loss (gain) on disposal of fixed assets | - | 3 | 108 | (6,206 | ) | ||||||||
| Adjusted operating income (Non-GAAP) | $ | 15,283 | $ | 13,701 | $ | 48,325 | $ | 33,071 | |||||
| Table 2: Adjusted Net Income and Diluted Common Share Outstanding Reconciliation | |||||||||||||
| (in thousands, except per share data) | |||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||
| September 30, | September 30, | ||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||
| Net income (GAAP) | $ | 11,694 | $ | 19,540 | $ | 33,316 | $ | 33,327 | |||||
| Adjustments (net of taxes): | |||||||||||||
| Acquisition Costs | - | 7 | - | 763 | |||||||||
| Change in fair value of contingent consideration | 177 | 2,485 | 2,442 | 6,942 | |||||||||
| Gain on sale of Molded Fiber | - | (11,602 | ) | - | (11,602 | ) | |||||||
| Loss (gain) on disposal of fixed assets | - | 2 | 80 | (4,609 | ) | ||||||||
| Adjusted net income (Non-GAAP) | $ | 11,871 | $ | 10,432 | $ | 35,838 | $ | 24,821 | |||||
| Adjusted Net Income per diluted share outstanding (Non-GAAP) | $ | 1.54 | $ | 1.37 | $ | 4.66 | $ | 3.25 | |||||
| Weighted average diluted common shares outstanding | 7,709 | 7,638 | 7,697 | 7,629 | |||||||||
| Table 3: Adjusted EBITDA Reconciliation | |||||||||||||
| (in thousands) | |||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||
| September 30, | September 30, | ||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||
| Net income (GAAP) | $ | 11,694 | $ | 19,540 | $ | 33,316 | $ | 33,327 | |||||
| Income tax expense | 2,447 | 5,699 | 8,694 | 9,620 | |||||||||
| Interest expense, net | 933 | 830 | 2,890 | 1,891 | |||||||||
| Depreciation | 1,741 | 1,696 | 5,142 | 5,874 | |||||||||
| Amortization of intangible assets | 1,099 | 1,116 | 3,304 | 3,264 | |||||||||
| EBITDA (Non-GAAP) | $ | 17,914 | $ | 28,881 | $ | 53,346 | $ | 53,976 | |||||
| Adjustments: | |||||||||||||
| Share based compensation | 1,197 | 897 | 3,450 | 2,370 | |||||||||
| Acquisition Costs | - | 10 | - | 1,027 | |||||||||
| Change in fair value of contingent consideration | 238 | 3,346 | 3,289 | 9,348 | |||||||||
| Gain on sale of Molded Fiber | - | (15,623 | ) | - | (15,623 | ) | |||||||
| Loss (gain) on disposal of fixed assets | - | 3 | 108 | (6,206 | ) | ||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 19,349 | $ | 17,514 | $ | 60,193 | $ | 44,892 | |||||
Q3 2023 EARNINGS RELEASE
